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Abstract
Background: p53 is the most commonly mutated tumor suppressor gene in human cancers. In
addition to the loss of tumor suppression function and exertion of dominant-negative effects over
the remaining wild-type protein, several p53 mutants can gain novel oncogenic functions (gain-of-
function, GOF) that actively regulate cancer development and progression. In human endometrial
cancer, p53 mutation is more often associated with aggressive nonendometrioid cancer. However,
it was unknown if p53 mutants contributed to endometrial cancer progression through the GOF
properties.
Methods: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and
invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-
regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression
vector or suppressing the p53 gene with short hairpin RNA.
Results: We found that forced over-expression of p53-R175H significantly promoted cell
migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/
phosphatidylinositol 3-kinase (PI3K)/AKT pathway. Conversely, suppression of p53-R175H with
short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of
EGFR/PI3K/AKT pathway.
Conclusion: These findings show for the first time that elevated expression of p53-R175H mutant
may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may
contribute to the invasive phenotype in endometrial cancer.
Introduction
Endometrial cancer (EC) is the commonest gynecologic
malignancy in the US and other Western nations [1].
Asian nations such as China and Japan have an incidence
that is 4-5 times lower than in Western nations [2]. How-
ever, the incidence of EC in Asian countries has markedly
increased in recent years [3]. Patients with advanced-stage
EC frequently exhibit a poor prognosis, even after radical
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These poor outcomes are closely associated with the pro-
gression and metastasis of the disease. Thus, a better
understanding of the molecular mechanisms underlying
the aggressive behavior of EC is necessary to identify
potential targets for efficient therapy.
The tumor suppressor gene TP53 regulates the expression
of genes involved in cell cycle arrest, apoptosis and DNA
damage repair [4]. TP53 is mutated in more than half of
human tumors. These mutations lead to single amino acid
changes that influence the sequence-specific binding or
the conformation of the mutant protein, abrogating its
ability to induce the transcription of target genes (loss of
function). It has been shown that p53 mutants exert dom-
inant negative effects on co-expressed wild-type p53
(dominant-negative effects) [5,6]. Previous studies also
indicated certain p53 mutations may confer oncogenic
properties (gain-of-function, GOF) beyond their negative
transdomination over the wild-type p53 tumor suppres-
sor functions. These GOF effects include enhanced cancer
cell proliferation and increased tumorigenicity in vivo [7-
10], suggesting that GOF activity of p53 mutation may
play an important role in tumor progression. However,
little is known about GOF effects on tumor cell invasive
activity. A common p53 mutant p53-R175H has been pre-
viously shown to possess a marked anti-apoptotic GOF in
lung cancer cells [11]. In human EC, p53 mutations are
more frequently identified in aggressive nonendometrioid
cancer [12]. However, the precise role and the molecular
mechanism of GOF properties of p53 mutants in EC pro-
gression and metastasis are poorly understood.
In this report, we sought to investigate the consequences
of up-regulation and down-regulation of GOF p53
mutant (p53-R175H) on EC cell migration and invasion.
Furthermore, we examined the molecular mechanisms by
which p53-R175H over-expression lead to invasive phe-
notype in EC. We showed, for the first time, that elevated
expression of p53-R175H in EC cells can display GOF
effects to promote the invasive potential by activation of
the EGFR/PI3K/AKT pathway.
Materials and methods
Cell lines and cell culture
The EC cell line KLE [13] harboring a p53 missense at
codon 175 (p53-R175H, CGC > CAC) was obtained from
the Cell Bank of the Chinese Academy of Sciences, Shang-
hai (China) and grown in Ham's F12 medium containing
10% heat-inactivated fetal bovine serum. The cells were
maintained at 37°C under a humidified 5% CO2 atmos-
phere.
Construction of expression vector expressing p53 GOF 
mutation p53-R175H and stable transfection
pCMV-p53 expression vector, which carries wt p53, was
purchased from Clontech Laboratories, Inc. The corre-
sponding empty vector named pCMV was made from
pCMV-p53 by removing p53 sequence and religating the
vector. pCMV-p53mt175 expression vector, which con-
tains mutant p53-R175H, was generated from pCMV-p53
by the QuickChange mutagenesis system (Stratagene) fol-
lowing the manufacturer's recommendations. The primer
sequence used for mutagenesis is 5'-GTGAGGCACT-
GCCCCCAC (forward) and 5'-GTGGGGGCAGTGCCT-
CAC-3' (reverse). The sequences of the mutation
constructs were verified with an ABI 3100 sequencer
(Applied Biosystems). Stable transfection of pCMV-
p53mt175 and pCMV vector was performed using Lipo-
fectamine PLUS Reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer's instructions. The trans-
fected cells were selected in medium containing G418
(200 mg/ml). Independent clones were isolated,
expanded, and screened for the expression of p53 protein
expression by Western blotting. KLE cells transfected with
pCMV-p53mt175 were designated R175H cells, and KLE
cells transfected with pCMV vector were designated Vector
cells.
Knockdown of p53 GOF mutation p53-R175H using short 
hairpin RNA
The pSUPER-p53 RNAi System [14] was used to generate
a stable KLE cell line with knocked-down p53 gene by an
RNAi approach as described earlier [15]. In brief, KLE cells
at 80% confluency were co-transfected with pSUPER-p53
and pPUR vector (BD Dickinson), or with pSUPER empty
vector and pPUR vector, in the ratio 3:1 using the Super-
fectR Transfection reagent (Qiagen), respectively. At 48 h
after transfection, selection was started using 200 μg/ml
G418 (Invitrogen). Resistant clones were characterized for
levels of p53 protein by western blot. KLE cells transfected
with pSUPER-p53 and pPUR were designated siRNA cells,
and KLE cells transfected with pSUPER and pPUR were
designated Control siRNA cells.
In vitro Matrigel invasion assay
Matrigel invasion assay was performed using a 24-well
invasion chamber system (BD Biosciences, Bedford, MA)
with Matrigel membrane (8.0-μm pore), as described in
our previous report [16]. Briefly, each 750 μl of Ham's F12
medium supplemented with 20% FBS and 10 μg/ml of
bovine fibronectin (chemoattractant) were placed in the
lower compartment of the chamber. In the prewarmed
and rehydrated upper compartment, 2 × 104 cells in 500
μl of Ham's F12 medium supplemented with 20% FBS
were added, and the cells were allowed to migrate through
the intermediate membrane for 24 h at 37°C. Membranes
were then fixed with 10% neutral-buffered formalin andPage 2 of 7
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lower side of the membrane were counted in 10 high-
powered (×200) fields under a microscope. Assays were
done in triplicate for each experiment, and each experi-
ment was repeated three times.
In vitro cell migration assay
This migration assay was a modification of the assay
described previously [17], which measured cell migration
through an 8.0-μm pored membrane (BD Biosciences,
Bedford, MA). In the lower chamber, 600 μl of Ham's F12
medium containing 20% FBS and 10 μg/ml of bovine
fibronectin was placed. 2 × 104 cells in 100 μl of Ham's
F12 medium supplemented with 20% FBS were placed in
the upper chamber. After 6 h-incubation, the number of
migrated cells (lower side of the membrane) was counted
as described above. Assays were done in triplicate for each
experiment, and each experiment was repeated three
times.
Western blot analysis
Whole cellular protein was obtained with M-Per Mamma-
lian Protein Extraction Reagent (Pierce, Rockford, IL). The
aliquots were separated on SDS-PAGE (10%) and trans-
ferred to nitrocellulose membranes. Antigen-antibody
complexes were detected ECL blotting analysis system
(Amersham Biosicences). The following primary antibod-
ies were used: p53 (DO-1, Santa Cruz Biotechnology),
EGFR antibody (2-18C9, Dako, Denmark), phosphor-
ylated EGFR antibody (pEGFR, Tyr1173, Santa Cruz Bio-
technology), AKT antibody (Cell Signaling Technology),
phosphorylated AKT antibody (p-AKT, Ser473, Santa Cruz
Biotechnology), ERK1/2 antibody (K-23, Santa Cruz Bio-
technology), phosphorylated ERK1/2 antibody (p-ERK1/
2, T183/Y185, Abcam plc) and G3PDH (sc-25778, Santa
Cruz Biotechnology). EGFR inhibitor PD153035 was
from Calbiochem.
Statistical analysis
Statistical analyses were performed using the SPSS 10.0
software package (SPSS Inc., IL). The invasion and migra-
tion assay was analyzed by two-sided Student's t test. Sta-
tistically significance was defined as P < 0.05.
Results
Forced over-expression of p53-R175H by cDNA 
transfection promoted cell invasion and migration
To evaluate whether p53-R175H expression associated
with the invasive potential in EC, we chose human EC
KLE cells to test the effects of forced over-expression of
p53 GOF mutation R175H because this cell line expresses
endogenous mutant p53-R175H. We transfected this cell
line with either pCMV-p53mt175 or empty pCMV vector.
The degree of p53-R175H protein expression was docu-
mented on Western blotting. As expected, Untransfected
KLE cells (UT) and Vector cells expressed detectable
amounts of p53-R175H, while R175H cells showed an
increased p53-R175H expression (Figure 1A). We next
compared the invasive activity of the cells in the Matrigel
invasion assay. In contrast to UT and Vector cells, R175H
cells showed a 2-fold increase in invasive migration
through the Matrigel (P < 0.05) (Figure 1B). To evaluate
the role of p53-R175H up-regulation on the motility
properties of KLE cells, we also compared the cell motility
using an in vitro cell migration assay. After 6 h-incuba-
tion, R175H cells were 3-fold more migratory than UT
and Vector cells (P < 0.05) (Figure 1C). These results sug-
gest that overexpression of p53-R175H can significantly
promote the invasive and migratory function of KLE cells.
Stable RNAi-mediated suppression of p53-R175H 
inhibited cell invasion and migration
To further investigate the invasion-inhibitory effect of
p53-R175H knockdown in KLE cells, we used RNAi
approach to down-regulate the endogenous expression of
p53-R175H in KLE cells. As shown in Figure 2A, UT and
Control siRNA cells expressed detectable amounts of p53-
Expression of p53-R175H is associated with enhanced inva-sion and migration in KLE cellFigure 1
Expression of p53-R175H is associated with enhanced 
invasion and migration in KLE cells. (A) Western blot 
analysis showing p53 expression of p53-R175H in KLE cells 
after they had been transfected with a vector containing p53-
R175H construct (R175H). Untransfected KLE cells (UT) and 
cells transfected with empty vector alone (Vector) served as 
the control. (B) Invasive ability of UT, R175H and Vector 
cells through the Matrigel-transwell membranes after 24 h of 
incubation. An asterisk indicates P < 0.05. UT and Vector 
cells served as the control. (C) Migratory property of UT, 
R175H and Vector cells through the transwell membranes 
after 6 h of incubation. An asterisk indicates P < 0.05. UT and 
Vector cells served as the control.Page 3 of 7
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expression, as confirmed by Western blotting. We next
tested the effects of p53-R175H down-regulation on can-
cer invasion and migration. Depletion of p53-R175H
expression caused a significant decrease in cell invasion
ability when compared to UT and Control siRNA cells (P
< 0.05) (Figure 2B). Down-regulation of p53-R175H also
significantly reduced KLE cell migration when compared
to UT and Control siRNA cells (P < 0.05) (Figure 2C).
These results suggest that repression of p53-R175H
expression can lead to cell invasion and migration inhibi-
tion in KLE cells.
p53-R175H induced activation of EGFR/PI3K/AKT 
pathway
Epidermal growth factor receptor (EGFR), a transmem-
brane phosphoglycoprotein, over-expressed in a variety of
solid tumors, including EC [18], is the key molecular
driver of oncogenesis and progression [19]. It has been
shown that activated EGFR strongly correlate with tumor
invasion and metastasis in EC [20]. Previous studies using
osteosarcoma cells showed an association between EGFR
and p53 mutations [21]. EGFR activation can lead to the
activation of the downstream PI3K/AKT pathway [22,23].
Therefore, in this study, we investigated the effect of p53-
R175H expression on EGFR/PI3K/AKT signal pathway
using Western blotting after up-regulation or down-regu-
lation of p53-R175H in KLE cells, respectively. When
comparing with UT cells or Vector cells, R175H cells
showed marked increase in constitutive activation of
EGFR (p-EGFR, Tyr1173) and AKT (pAKT, Ser473) (Figure
3A). Conversely, the down-regulation of p53-R175H
expression by RNAi resulted in inactivation of EGFR and
AKT (Figure 3B). Because EGFR activation also results in
the activation of the downstream MEK/ERK pathways, we
next investigated the effect of p53-R175H expression on
these pathways. Western blot analysis showed that no sig-
nificant change in the levels of pERK1/2 was observed in
R175H or Vector cells (Figure 3A). These findings suggest
Down-regulation of p53-R175H results in decreased cell invasion and migrationFigure 2
Down-regulation of p53-R175H results in decreased 
cell invasion and migration. (A) Expression of p53-
R175H in KLE cells was inhibited by pSUPER-p53 vector 
(siRNA) as described in Materials and Methods. Cells were 
harvested and subjected to Western blotting to determine 
mutant p53 expression. Untransfected KLE cells (UT) and 
cells transfected with pSUPER empty vector (Control siRNA) 
served as the control. (B) Invasive ability of UT, siRNA and 
control siRNA cells through the Matrigel-transwell mem-
branes after 24 hours of incubation. An asterisk indicates P < 
0.05. UT and Control siRNA cells served as controls. (C) 
Migration potential of UT, siRNA and Control siRNA cells 
through the transwell membranes after 6 hours of incuba-
tion. An asterisk indicates P < 0.05. UT and Control siRNA 
cells were used as controls.
p53-R175H induces activation of EGFR/PI3K/AKT pathwayFigure 3
p53-R175H induces activation of EGFR/PI3K/AKT 
pathway. (A) Western blot analysis showing p53 expression 
in R175H, UT and Vector cells. UT and Vector cells served 
as the control. The membranes were stripped and probed 
with anti-pEGFR (pY1173), total EGFR, pAKT (ser473), total 
AKT antibody, pERK1/2, or total ERK1/2. The membranes 
were probed with anti-G3PDH antibody to assure even load-
ing of proteins in each lane. (B) Expression of p53-R175H in 
KLE cells was inhibited by pSUPER-p53 vector (siRNA) as 
described in Materials and Methods. Cells were harvested 
and subjected to Western blot to determine mutant p53 
expression. UT and Control siRNA cells served as the con-
trol. Membranes were stripped and probed with anti-pEGFR 
(pY1173), total EGFR, pAKT (ser473), or total AKT antibody. 
G3PDH was determined to ensure even loading of proteins 
in each lane.Page 4 of 7
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KLE cells is dependent of EGFR/PI3K/AKT, but not EGFR/
MEK/ERK signaling pathway.
p53-R175H-induced AKT signaling is mediated by EGFR 
activation
To further determine whether p53-R175H-induced
increases in cell invasion and migration were EGFR-
dependent, we performed the Matrigel invasion assay and
migration assay in the presence of the EGFR inhibitor
PD153035. At the concentration of 20 μM, pretreatment
of KLE cells with EGFR inhibitor PD153035 caused signif-
icant reductions in cell invasion, and migration in R175H
cells, respectively (Figure 4A and 4B). Although this treat-
ment also decreased cell invasion and migration in Vector
cells, the degree of inhibition was much less marked than
that in R175H cells. Next, we sought to explore whether
p53-R175H-induced PI3K/AKT signaling is mediated by
EGFR activation, we pretreated KLE cells with specific
EGFR tyrosine kinase inhibitor PD153035 (20 μM) for 2
h. Western blot analysis indicated that PD153035 signifi-
cantly inhibited p53-R175H-induced EGFR and AKT acti-
vation (Figure. 4C). These results suggested that p53-
R175H expression may promote the invasive function of
EC cells, at least in part through the activation of EGFR/
PI3K/AKT pathway.
Discussion
Previous studies have demonstrated that gain-of-function
of p53 cancer mutants could play important roles in car-
cinogenesis of various types of human cancers [24]. For
example, p53 mutants can enhanced tumorigenic poten-
tial in nude mice and enhanced plating efficiency in agar
cell culture [25]. These gain-of-functions of p53 cancer
mutants acquire novel oncogenic activities, which may
account for the close correlation between the expression
of p53 mutants and the poor prognosis of patients with
EC [26]. Moreover, p53 mutations are frequently detected
in patients with high-grade serous and clear cell carcino-
mas, which are associated with an aggressive clinical
course [12], suggesting the possibility that p53 mutations
mediate features of the invasive and metastatic behavior
of EC cells. However, little information is available
regarding the consequence of GOF p53 mutant expression
in EC progression. Therefore, in this study, we investi-
gated the possible GOF roles of mutant p53 protein
R175H in cell invasion and migration in EC KLE cells. Our
data suggested that up-regulation of p53-R175H dramati-
cally enhanced cell invasion and migration in KLE cells as
shown in cell invasion and migration assay (Figure. 1).
Conversely, down-regulation of p53-R175H by siRNA sig-
nificantly attenuated the invasive potential of KLE cells
(Figure. 2). Previous study showed p53-R175H can
endow p53-negative T-ALL cells with the capacity to dis-
seminate, and induce lymphohematopoietic metastatic
potential and tissue invasiveness in SCID mice [27]. Thus,
our results provided the in vitro evidence in support of the
role of GOF activities of certain p53 mutant as an onco-
gene in EC progression.
Ample evidences support the critical role EGFR in tumor
growth and progression, including angiogenesis, tumor
cell proliferation and metastasis [19]. EGFR expression is
increased in various cancer types, including endometrial
cancer [18]. High levels of EGFR protein expression
strongly correlates with tumor metastasis and poor prog-
nosis in EC [28,29]. Previous study showed an association
between p53 mutation and EGFR in bladder cancer [30].
Mutant p53-R175H has also been shown to activate the
EGFR promoter in human osteosarcoma Saos-2 cells [21].
EGFR activation triggers the downstream PI3K/AKT and
MEK/ERK signaling pathways [31]. Therefore, in this
study, we determined the possible mechanisms by which
p53-R175H could promote invasion ability in EC cells in
regulation of EGFR/PI3K/AKT and EGFR/MEK/ERK path-
way. Our present data suggested that over-expression of
p53-R175H led to enhanced EGFR phosphorylation, and
subsequently activation of PI3K/AKT pathway, but had no
effect on the MEK/ERK pathway in KLE cells (Figure. 3).
p53-R175H-induced AKT signaling is mediated by EGFR acti-vationFigure 4
p53-R175H-induced AKT signaling is mediated by 
EGFR activation. (A) R175H, UT and Vector cells were 
seeded in 12-well plates and treated with PD153035 (20 μM). 
Cell invasion and migration assay were performed at 24 h and 
6 h post treatment, respectively. An asterisk indicates P < 
0.05. (B) R175H, UT and Vector cells were pretreated with 
PD153035 (20 μM) for 2 h and harvested for Western blot. 
Membranes were stripped and probed with anti-pEGFR 
(pY1173), total EGFR, pAKT (ser473), or total AKT antibody. 
G3PDH was determined to ensure even loading of proteins 
in each lane.Page 5 of 7
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expression of EGFR in prostate and ovarian cancer was
associated with activation of the PI3K/AKT signaling path-
way [22,23]. Moreover, treatment of EGFR inhibitor abol-
ished p53-R175H-induced cell invasion and migration
and attenuated activation of AKT (Figure. 4), suggesting
GOF effects of this mutant could drive invasive character-
istics in EC cells through EGFR/PI3K/AKT-dependent
pathway. However, our study is still limited for utilizing
the cell line that expresses p53-R175H. Further experi-
ments using p53-null EC cell lines are needed to confirm
whether or not this mutation can show GOF properties to
activate the EGFR/PI3K/AKT pathway, subsequently to
enhance EC metastasis.
Overall, the results of this study show the possibility that
GOF activity of p53-R175H contributes to an aggressive
phenotype to EC cells, at least in part through the ability
of p53-R175H to associate with active EGFR, subse-
quently resulting in the activation of its downstream
PI3K/AKT signaling pathway.
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